Develop Genetic Medicines For Cns Diseases
03/01/2024 13:26
Jan 3 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4D MOLECULAR THERAPEUTICS: CO & ARBOR BIOTECHNOLOGIES
PARTNER TO
CO-DEVELOP, CO-COMMERCIALIZE NEXT-GENERATION GENETIC MEDICINES
FOR CNS DISEASES
* 4D MOLECULAR THERAPEUTICS: 4DMT AND ARBOR WILL CO-DEVELOP
AND
CO-COMMERCIALIZE UP TO SIX AAV-DELIVERED CRISPR/CAS-BASED
THERAPEUTIC CANDIDATES
Source text for Eikon: ID:nGNX92Y8lH
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings